View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, March 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on March 2, 2026, the Compensation Committee of Taysha's Board of Directors granted one new employee restricted stock units (RSUs) representing 156,870 shares of the Company’s common stock and an opt...

 PRESS RELEASE

Texas Capital Earns Best Bank Award for Middle Market Banking in the U...

Texas Capital Earns Best Bank Award for Middle Market Banking in the U.S. (West) Clients cite strong satisfaction with the firm’s middle market banking DALLAS, March 03, 2026 (GLOBE NEWSWIRE) -- Texas Capital announced today that it has been named as a Best Bank – Likelihood to Recommend for Middle Market Banking in the U.S. (West) by Crisil Coalition Greenwich, recognizing the firm’s approach to serving middle market companies through its client-focused, full-service banking platform. Texas Capital serves small business, middle market and corporate clients across industries and geogra...

 PRESS RELEASE

Rocky Mountain Chocolate Factory Launches Omnichannel Growth Strategy;...

Rocky Mountain Chocolate Factory Launches Omnichannel Growth Strategy; Systemwide Rollout Underway Expands Digital Marketplace and Catering Access to Increase Consumer Touchpoints, Strengthen Unit Economics, and Support Data-Driven Growth DURANGO, Colo., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rocky Mountain Chocolate Factory, Inc. (NASDAQ: RMCF), America’s Chocolatier®, today announced the launch of its omnichannel growth strategy, marking the next phase of the company’s broader transformation initiative. Systemwide rollout is underway and expected to be substantially implemented over the ne...

 PRESS RELEASE

Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financi...

Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results – ZYNRELEF® and APONVIE® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise– Achieved $154.9 Million in 2025 Net Revenue– Issues Full-Year 2026 Net Revenue Guidance of $173 to $183 Million and Adjusted EBITDA of $10 to $20 Million CARY, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2025, and highlighted ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 25, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

RXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 Gui...

RXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 Guidance ALISO VIEJO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter and full year ended December 31, 2025. Strategic Highlights and Recent Developments 2025 Light Adjustable Lens (LAL® and LAL+®) unit sales increased 12% to 109,615Over 300,000 RxSight LAL procedures performed since launch, reinforcing the benefits of post-operative adjustability in clinical practiceLight Delivery Devices (LDD™) installed base expanded to 1,134, providing a strong f...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 19, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financi...

Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 CARY, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Thursday, February 26, 2026, at 8:30 a.m. ET to report fourth quarter and full year 2025 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following  which will provide partic...

 PRESS RELEASE

Sound Financial Bancorp, Inc. Announces Annual Shareholders Meeting Da...

Sound Financial Bancorp, Inc. Announces Annual Shareholders Meeting Date SEATTLE, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Sound Financial Bancorp, Inc. (NASDAQ: SFBC) (the “Company”) announced today that the Company’s annual meeting of shareholders will be held on Tuesday, May 26, 2026. The record date for shareholders entitled to vote at the annual meeting will be March 31, 2026. About the Company Sound Financial Bancorp, Inc., a bank holding company, is the parent company of Sound Community Bank, and is headquartered in Seattle, Washington with full-service branches in Seattle, Tacoma, Moun...

 PRESS RELEASE

RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Re...

RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 ALISO VIEJO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the fourth quarter and full year 2025 after the market close on Wednesday, February 25, 2026. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conferen...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 7, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 6, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on February 2, 2026, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, restricted stock units (RSUs) representing 349,000 shares of the Company’s...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 4, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 2, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: January 31, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: January 27, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch